Ilaris (Canakinumab)

Ilaris (canakinumab) modulates the interleukin‑1β driven inflammatory cascade, providing disease control in several autoinflammatory and arthritic conditions.

• Cryopyrin‑Associated Periodic Syndromes (CAPS): reduces frequency and severity of fever attacks and improves quality of life.
• Familial Cold Autoinflammatory Syndrome: prevents cold‑induced inflammatory episodes and associated symptoms.
• Muckle‑Wells Syndrome: diminishes rash, arthralgia, and progressive hearing loss by controlling systemic inflammation.
• Neonatal‑Onset Multisystem Inflammatory Disease: controls multisystem inflammation and organ damage in affected infants.
• Systemic Juvenile Idiopathic Arthritis: achieves sustained remission of joint inflammation and systemic features.
• Gouty Arthritis (off‑label): lowers acute gout flare intensity and accelerates symptom resolution.

• Canakinumab is a fully human monoclonal antibody that selectively binds soluble and membrane‑bound interleukin‑1β with high affinity. By neutralising IL‑1β, it blocks downstream signalling through the IL‑1 receptor, preventing activation of NF‑κB and MAPK pathways that mediate fever, leukocyte recruitment and tissue damage. This targeted inhibition curtails the inflammatory cascade responsible for autoinflammatory syndromes and related arthritic conditions.

The safety profile of Ilaris reflects its immunomodulatory action, with most patients experiencing mild to moderate reactions.

Common Side Effects

• Injection site pain: mild tenderness or erythema at the injection site.
• Upper respiratory tract infection: nasopharyngitis or sinusitis.
• Headache: transient mild headache.
• Diarrhoea: loose stools without severe dehydration.
• Nausea: occasional mild nausea.

Serious or Rare Side Effects

• Serious infection: opportunistic bacterial, viral or fungal infections.
• Allergic reaction: anaphylaxis or severe hypersensitivity.
• Neutropenia: marked reduction in neutrophil count.
• Hepatitis: elevated liver enzymes indicating liver injury.
• Malignancy: potential increased risk of certain cancers (monitoring advised).

Before initiating Ilaris, clinicians should evaluate several safety considerations to minimise risk.

• Infection screening: assess for active or latent infections, especially tuberculosis, before treatment.
• Vaccination status: administer required vaccines prior to first dose; avoid live vaccines during therapy.
• Hematologic monitoring: regularly check complete blood count for neutropenia or thrombocytopenia.
• Liver function: monitor hepatic enzymes periodically during treatment.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with patient.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the vial.

Canakinumab may interact with other medicines that affect immune function or infection risk.

Major Interactions (Avoid)

• Live vaccines: concurrent use can cause severe infection; avoid during therapy.
• Immunosuppressants: combined use may markedly increase infection risk.
• Antiviral agents for chronic infections: may reduce efficacy of viral control.

Moderate Interactions (Monitor Closely)

• Cytotoxic chemotherapy: monitor blood counts for additive myelosuppression.
• Antifungal agents (e.g., azoles): observe for enhanced immunosuppression.
• Concomitant biologics (e.g., TNF inhibitors): assess for overlapping infection risk.